TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Key Inclusion Criteria:~* Subjects must be able to understand and agree to comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications~* Subjects chronically infected with hepatitis C virus (HCV) genotype 3~* Subjects who are HCV treatment-naive~* Subjects who are HCV treatment-experienced (previous exposure to non-structural 5A inhibitors is prohibited)~* HCV RNA ≥10,000 IU/mL at screening~Key Exclusion Criteria:~* HCV Genotypes other than genotype-3 infection; mixed genotype infections are not permitted~* Liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair~* Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening~* Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed)~* Evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1:Daclatasvir + Sofosbuvir in treatment-naive subjects (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
- A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy of CDZ173 in Patients With APDS/PASLI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male and female patients 12 to 75 years of age (inclusive), who had a documented APDS/PASLI-associated genetic PI3K delta mutation.~* In Part I and Part II, patients must had nodal and/or extranodal lymphoproliferation, and clinical findings and manifestations compatible with APDS/PASLI such as a history of repeated oto-sino-pulmonary infections and/or organ dysfunction (e.g., lung, liver). Additionally, in part II, patients must had at least one measurable nodal lesion on a CT or MRI scan.~* At screening, vital signs (systolic and diastolic blood pressure and pulse rate) were assessed in the sitting position after the patient rested for at least three minutes.~Key Exclusion Criteria:~* Previous or concurrent use of immunosuppressive medication.~* Current use of medication known to be strong inhibitor or moderate or strong inducers of isoenzyme CYP3A, if treatment cannot be discontinued or switched to a different medication prior to starting study treatment.~* Current use of medications that are metabolized by isoenzyme CYP1A2 and have a narrow therapeutic index (drugs whose exposureresponse indicates that increases in their exposure levels by the concomitant use of potent inhibitors may lead to serious safety concerns (e.g., Torsades de Pointes)).~* Administration of live vaccines (this includes any attenuated live vaccines) starting from 6 weeks before study entry, during the study and up to 7 days after the last dose of CDZ173.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study medication and for 2 days after stopping study treatment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part I: CDZ173 (Type: EXPERIMENTAL): Participants consecutively received CDZ173 10 mg twice a day (b.i.d.) from Day 1 to Day 28, CDZ173 30 mg b.i.d. from Day 29 to Day 56 and CDZ173 70 mg b.i.d. from Day 57 to Day 84.
- Part II: CDZ173 (Type: EXPERIMENTAL): Participants received CDZ173 70 mg b.i.d. from Day 1 to Day 85.
- Part II: Placebo (Type: PLACEBO_COMPARATOR): Participants received Placebo b.i.d. from Day 1 to Day 85.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have been enrolled in the first phase~2. Recurrent Plasmodium falciparum infection with clinical symptoms.~3. Parents' or guardians' willingness and ability to comply with the study protocol for the duration of the study.~4. Signed (or thumb-printed whenever parents/guardians are illiterate) (second) informed consent by the parents or guardians. Note: the informed consent will cover the whole period of the study, including additional active follow ups~Exclusion Criteria:~Patients with at least one of the following criteria will be excluded:~1. Participation in any other investigational drug study (antimalarial or others) during the previous 30 days.~2. Known hypersensitivity and previous Serious Adverse Events related to the study drugsto the study drugs.~3. Severe malaria( WHO 2000) or danger signs: not able to drink or breast-feed, vomiting (\> twice in 24hours), recent history of convulsions (\>1 in 24h), unconscious state, unable to sit or stand.~4. Presence of intercurrent illness or any condition (cardiac, renal, hematologic, hepatic diseases) which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study, including known G6PD deficiency.~5. Patients who are taking drug which may prolong the QT (imidazole and triazole, antifungal agent).~6. Severe malnutrition (defined as weight for height \<70% of the median NCHS/WHO reference).~7. Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole for the prevention of Pneumocisti carini pneumonia in children born to HIV+ women.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Artemether/Lumefantrine (Type: EXPERIMENTAL): Tablets 20 mg/120 of Artemether/Lumefantrine will be given to 124 trial patients
- Artesunate/Amodiaquine (Type: EXPERIMENTAL): Tablets 25mg/67,5 mg of Artesunate/Amodiaquine will be given to 124 trial patients.
- Quinine + Clindamycin (Type: ACTIVE_COMPARATOR): Quinine tablet 125mg + Clindamycin syrup 75mg/5ml will be given to 60 children.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of SCLC.~* First recurrence of SCLC after therapy with one prior chemotherapy regimen at initial diagnosis.~* Relapsed SCLC of any duration (both sensitive and resistant relapse).~* ECOG performance status of \</= 2.~* Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.~* No prior therapy with bevacizumab or any other VEGF inhibitor or topotecan~Exclusion Criteria:~* Uncontrolled emesis, regardless of etiology.~* Active uncontrolled infection.~* GI conditions or drugs that could impact absorption of oral topotecan.~* Known hypersensitivity to any component of topotecan capsule or compounds chemically related to topotecan.~* Uncontrolled hypertension with BP\>150/100.~* Prior h/o hypertensive crisis or encephalopathy.~* NYHA Grade II or greater congestive heart failure.~* H/O myocardial infarction within 6 months.~* H/O stroke or TIA within 6 months.~* H/O thrombotic or hemorrhagic disorders.~* Clinically significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.~* Anticipation of need for major surgical procedure during the study.~* Minor surgical procedures within 7 days prior to treatment start (placement of vascular access devices is permitted).~* H/O abdominal fistula, GI perforation, or intra-abdominal abscess within prior 6 months. Serious, non-healing wound, active ulcer, or untreated bone fracture. - H/O hemoptysis within prior 1 month.~* Concurrent radiotherapy.~* H/O whole lung radiation within 90 days prior to start of treatment.~* Presence or h/o central nervous system or brain metastases.~* H/o another malignancy other than SCLC.~* Concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment of small cell lung cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label, Single arm (Type: EXPERIMENTAL): Oral topotecan + IV Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgetic and Anxiolytic Effect of Preoperative Pregabalin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of disc prolapse~* Age 18+~* ASA (American Association in Anesthesiology) I-III~* written consent~Exclusion Criteria:~* Age \< 18~* ASA \> III~* liver failure~* renal failure~* allergic reaction against gabapentin and/or pregabalin~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): 150 mg Pregabalin per orally about one hour before surgery
- Placebo (Type: PLACEBO_COMPARATOR): One capsule of saccharose (placebo) was administered orally about one hour before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Age above or equal to 18, no upper limit Patient has been treated and followed up for more than 6 months by the same general practitioner (GP) Hypertension treated for at least 3 months and not under control at the time of inclusion in the study \[systolic blood pressure (SBP) above or equal to 140 mmHg and diastolic blood pressure (DBP) above or equal to 90 mmHg, or SBP above or equal to 130 mmHg and DBP above or equal to 80 mmHg if patient has chronic renal insufficiency or diabetes\] Results available from at least two tests of albuminuria Antihypertensive treatment remained unchanged during the month prior data collection Decision by the GP to introduce telmisartan (either in combination with hydrochlorthiazide \[HCTZ\] or not) in the antihypertensive treatment (normal prescription) Written informed consent of the patient to collect his/her data~Exclusion criteria:~Blood pressure under control \[SBP below 140 mmHg and DBP below 90 mmHg or SBP below 130 mmHg and DBP below 80 mmHg if patient has chronic renal insufficiency or diabetes\] The patient refuse to allow his/her data to be collected Women of childbearing potential not using an effective contraception method, as well as women who are breastfeeding Patients with proteinuria above or equal to 1g/l or with glomerular filtration rate (GFR) below 15 ml/min/1.73 m² Current or prior use of telmisartan within the last 12 months Change in the antihypertensive treatment during the month prior to collection of the data

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan (Type: None): None
- Telmisartan + hydrochlorothiazide (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of DNA Fragmentation in Sperm on Pregnancy Outcome After Intra-uterine Insemination in a Spontaneous Cycle

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Couples seeking fertility treatment after at least 12 months of unprotected intercourse are eligible. All couples underwent basic fertility investigations which included semen analysis, evaluation of menstrual cycle, and tubal patency testing.~Exclusion Criteria:~Double sided tubal disease, severe endometriosis (classified as revised American Society for Reproductive Medicine stage III or IV), premature ovarian failure, and known endocrine disorders (such as Cushing's syndrome or adrenal hyperplasia), azoö- or necrozoospermia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Spontaneous cycle IUI (Type: EXPERIMENTAL): DNA fragmentation by TUNEL assay~DNA fragmentation will be measured both at the time of the diagnostic work-up as at the time of insemination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Remifentanil Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II status~* aged 18-60 years old~* presenting for ureterorenoscopy~Exclusion Criteria:~* history of hypertension~* asthma and chronic obstructive lung disease~* recent respiratory tract infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ultiva,remifentanil,opioid,analgesic (Type: ACTIVE_COMPARATOR): Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
- control (Type: NO_INTERVENTION): Control:Remifentanil stopped at the end of the surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of solar lentigines that occurred after adulthood~* age of 20 years or older.~Exclusion Criteria:~* uncontrolled systemic or chronic disease~* hypersensitivity to the ingredients of the ointment~* current use of skin whitening agents~* a history of other laser treatments within the past 6 months~* pregnancy~* lactation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- epidermal growth factor (EGF) containing ointment group (Type: EXPERIMENTAL): The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
- Vehicle ointment group (Type: PLACEBO_COMPARATOR): The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven classical Hodgkin lymphoma~* First diagnosis, no previous treatment, age: 18-60 years~* Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease~Exclusion Criteria:~* Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)~* Previous malignancy~* Prior chemotherapy or radiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BrECAPP (Type: ACTIVE_COMPARATOR): modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
- BrECADD (Type: ACTIVE_COMPARATOR): modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-menopausal patients between age of 20 and 50.~* Patients with cervical intraepithelial neoplasia 3(CIN3).~* Only infection with HPV type 16.~* Patients with Capable of observation of all of lesions by Colposcopy biopsy.~* Be informed of the nature of the study and will give written informed consent.~* Be agree with contraception during study~* White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 /mm\^3~* Normal for EKG(Electrocardiography)~* AST/ALT : 2.5 times less than normal range~Exclusion Criteria:~* Autoimmune Disease or Prohibited drug(Therapy) bring about immunosuppressive.~* Patient that has medical history of hypersensitivity about Food containing Lactic acid bacteria or Lactic acid bacteria medication.~* Patient with Acute illness(ex. Acute Appendicitis, Myocardial infarction, Hemorrhage, meningitis etc.)~* Investigational product within three months before the start of the drug administration to patients treated with other test drug.~* Patient with Chronic pancreatitis currently or Patients diagnosed with acute pancreatitis.~* Organopathy Patient with Inflammatory intestine·bowel disease, gastrointestinal tumors, ulcers, bleeding, perforation etc.~* Pregnant or lactating women~* Patient with HBV or HCV infection (except for Asymptomatic)~* Patient that Investigator judge~* Deemed inappropriate for researchers to judge the patient

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- BLS_ILB_E710c 500mg (Type: EXPERIMENTAL): * Drug: BLS_ILB_E710c 500mg~* Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 \& 8)
- BLS_ILS_E710c 1000mg (Type: EXPERIMENTAL): * Drug: BLS_ILS_E710c 1000mg~* Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 \& 8)
- BLS_ILS_E710c 1500mg (Type: EXPERIMENTAL): * Drug: BLS_ILS_E710c 1500mg~* Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 \& 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete